John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health, reacts to the National Comprehensive Cancer Network's call to expand comprehensive genomic testing across several cancers.
John Fox, MD, MHA, vice president of cinical transformation at Spectrum Health, reacts to the National Comprehensive Cancer Network's (NCCN's) call to expand comprehensive genomic testing across several cancers.
Transcript
At the most recent NCCN Annual Meeting, guidelines called for expanded comprehensive molecular profiling across several cancers. Do these changes present new reimbursement challenges?
The NCCN has recommended that we do comprehensive molecular profiling on more and more cancer types. It’s fascinating because the cost of genomic profiling is now in the range of $2500 to $3000. If you look at the cost of the therapies we’re using, they may be, if you’re using a monoclonal antibody, $8000, $10,000, $15,000 a month, and if we’re using those in combination, it’s even more. So, if in fact those molecular profiles help better identify which patients are likely to respond to which therapies, it’s a good value, because they’re spending thousands, tens of thousands of dollars a month on treatment, that if ineffective, is a waste of dollars and a waste of resources and a cost to the patient.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More